Medicenna Therapeutics
Tracked across 3 events · 18 articles · First seen Apr 14, 2026 · Last active Jun 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Medicenna Therapeutics will present a corporate update and preclinical data for MDNA113 at the 2026 Bloom Burton & Co. Healthcare Investor Conference, potentially increasing investor interest.
Apr 14, 2026 · 6 articles
Business
Impact: Medicenna Therapeutics successfully closed a public offering, raising CDN$4.44 million, which will support its lead programs and ongoing operations. This financing strengthens its financial position for developing Superkines targeting cancer and autoimmune diseases.
May 28, 2026 · 6 articles
Business
Impact: Medicenna Therapeutics has strengthened its intellectual property portfolio with new patent grants in the US, Australia, and Canada, covering its Superkine platforms and lead clinical programs. This enhances the company's competitive position and potential for future revenue.
Jun 11, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Medicenna Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard